Austar Lifesciences Ltd. (HK:6118) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Austar Lifesciences Limited has released its interim financial results for the first half of 2024, showcasing a return to profitability with a profit before income tax of RMB 9,186,000, compared to a loss in the same period in 2023. The company reported a gross profit of RMB 145,417,000 and a modest increase in gross profit margin to 20.75%, despite a decrease in revenue from the previous year. The results indicate a positive shift in the company’s financial performance, with basic and diluted earnings per share both at RMB 0.01.
For further insights into HK:6118 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money